Expression of stanniocalcin 1 as a potential biomarker of gastric cancer

Oncology (Switzerland)

Volumn 83, Issue 3, 2012, Pages 158-164

  Arigami, Takaaki ^a,b   Uenosono, Yoshikazu ^b   Ishigami, Sumiya ^a   Hagihara, Takahiko ^a   Haraguchi, Naoto ^a   Matsushita, Daisuke ^a   Yanagita, Shigehiro ^a   Nakajo, Akihiro ^a   Okumura, Hiroshi ^a   Hokita, Shuichi ^c   Natsugoe, Shoji ^a,b  

^a Field of Oncology ^*  (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c Jiaikai Imamura Hospital   (Japan)

Author keywords

Blood marker; Gastric cancer; Reverse transcription polymerase chain reaction; Stanniocalcin 1; Tumor progression

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; HYPOCALCIN; MESSENGER RNA; STANNIOCALCIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864817134     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000341390     Document Type: Article

References (30)

1. Statistics and Information Department, Ministry of Health, Labor, and Welfare: Vital Statistics of Japan 2004. Tokyo, Health and Welfare Statistics Association, 2006.
2. Ohtsu A: Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 2005;8:95-102. (Pubitemid 40655518)
3. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, ACTS-GC Group: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. (Pubitemid 350044801)
4. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-221.
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
6. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791. (Pubitemid 39095313)
7. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-3221.
8. Hiraiwa K, Takeuchi H, Hasegawa H, Saikawa Y, Suda K, Ando T, Kumagai K, Irino T, Yoshikawa T, Matsuda S, Kitajima M, Kitagawa Y: Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol 2008;15:3092-3100.
9. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH: Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556-1563.
10. Chang AC, Janosi J, Hulsbeek M, de Jong D, Jeffrey KJ, Noble JR, Reddel RR: A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol 1995;112:241-247.
11. Olsen HS, Cepeda MA, Zhang QQ, Rosen CA, Vozzolo BL: Human stanniocalcin: a possible hormonal regulator of mineral metabolism. Proc Natl Acad Sci USA 1996;93:1792-1796. (Pubitemid 26082959)
12. Wagner GF, Jaworski EM, Haddad M: Stanniocalcin in the seawater salmon: structure, function, and regulation. Am J Physiol 1998;274:1177-1185.
13. Chang AC, Reddel RR: Identification of a second stanniocalcin cDNA in mouse and human: stanniocalcin 2. Mol Cell Endocrinol 1998;141:95-99. (Pubitemid 28393383)
14. Ishibashi K, Imai M: Prospect of a stanniocalcin endocrine/paracrine system in mammals. Am J Physiol Renal Physiol 2002;282:367-375.
15. Chang AC, Jellinek DA, Reddel RR: Mammalian stanniocalcins and cancer. Endocr Relat Cancer 2003;10:359-373. (Pubitemid 37267555)
16. Yeung HY, Lai KP, Chan HY, Mak NK, Wagner GF, Wong CK: Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology 2005;146:4951-4960. (Pubitemid 41446634)
17. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J: Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst 2010;102:812-827.
18. He LF, Wang TT, Gao QY, Zhao GF, Huang YH, Yu LK, Hou YY: Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells. J Biomed Sci 2011;18:39.
19. Shirakawa M, Fujiwara Y, Sugita Y, Moon JH, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Mori M, Doki Y: Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma. Oncol Rep 2012;27:940-946.
20. Yeung BH, Law AY, Wong CK: Evolution and roles of stanniocalcin. Mol Cell Endocrinol 2012;349:272-280.
21. Wascher RA, Huynh KT, Giuliano AE, Hansen NM, Singer FR, Elashoff D, Hoon DS: Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. Clin Cancer Res 2003;9:1427-1435. (Pubitemid 36418397)
22. Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE, Hoon DS: Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res 2007;13:4105-4110. (Pubitemid 47105972)
23. Tamura S, Oshima T, Yoshihara K, Kanazawa A, Yamada T, Inagaki D, Sato T, Yamamoto N, Shiozawa M, Morinaga S, Akaike M, Kunisaki C, Tanaka K, Masuda M, Imada T: Clinical significance of STC1 gene expression in patients with colorectal cancer. Anticancer Res 2011;31:325-329.
24. Du YZ, Gu XH, Li L, Gao F: The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer. J Surg Oncol 2011;104:836-840.
25. Arigami T, Natsugoe S, Uenosono Y, Arima H, Mataki Y, Ehi K, Yanagida S, Ishigami S, Hokita S, Aikou T: Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer 2005;93:688-693. (Pubitemid 41486460)
26. Arigami T, Natsugoe S, Uenosono Y, Mataki Y, Ehi K, Higashi H, Arima H, Yanagida S, Ishigami S, Hokita S, Aikou T: Evaluation of sentinel node concept in gastric cancer based on lymph node micrometastasis determined by reverse transcription-polymerase chain reaction. Ann Surg 2006;243:341-347. (Pubitemid 43327765)
27. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds): AJCC Cancer Staging Manual, ed 7. New York, Springer, 2010.
28. Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, Anami K, Motoshita J, Ito M, Tanaka S, Yoshida K, Yasui W: Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer 2009;125:2383-2392.
29. Hsu SM, Raine L, Fanger H: Use of avidinbiotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580. (Pubitemid 11147380)
30. Matsusaka S, Chìn K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Mizunuma N, Hatake K: Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci 2010;101:1067-1071.